Valdecoxib is a nonsteroidal antiinflammatory drug, and it is listed in class 2 of biopharmaceutic classification of drugs. Valdecoxib is a poorly water-soluble and highly permeable drug. In the present study a new dissolution medium was developed, as there is no official dissolution medium available in the literature. The composition of the dissolution medium was selected on the basis of solubility data at 37°. Solubility data revealed that addition of surfactant may be suitable as dissolution medium. The concentration of 0.6% w/v sodium lauryl sulphate in water could be a suitable dissolution medium. The discriminating power of the selected dissolution medium (0.6% sodium lauryl sulphate in water) relative to the other dissolution mediums was evaluated. The selected dissolution medium was used for the evaluation of valdecoxib tablets.
Valdecoxib (VAL) is a new nonsteroidal antiinflammatory power of the selected dissolution medium was evaluated drug (NSAID)
1 . It is a selective inhibitor of the using prepared and commercial formulations. cyclooxygenase-2 (COX-2) and exhibits many of the pharmacological actions of prototypical NSAIDs, including VAL was a gift sample from M/s IPCA Laboratories Ltd., antiinflammatory, analgesic and antipyretic activity 2 . It is Mumbai. Two brands of VAL tablets Valus (Glenmark not official in any pharmacopoeia. The testing of Pharmaceuticals Ltd., Mumbai) and Revaldo-20 (Bangalore pharmaceutical dosage forms for in vitro drug release and Pharmaceutical Research Laboratories, Bangalore) were dissolution characteristics is very important for ensuring purchased from the local market. Sodium lauryl sulphate, batch-to-batch quality control and to optimize formulations Tween 80 and ethanol were purchased from Qualigens during drug development. Drugs that are practically Fine Chemicals, Mumbai. All other materials were of insoluble (less than 0.01%) need special attention during analytical reagent grade. dissolution testing for proper in vitro-in vivo correlation. Since the dissolution may be a rate limiting step in the in
The apparent solubility of VAL in water or in presence vivo absorption process, there is a need for developing of co-solvent or surfactant in water was determined at 37°. an appropriate dissolution medium 3 .
VAL (50 mg) was added to 50 ml of water in a conical flask with Teflon-lined screw caps. The conical flasks Approaches usually used in the design of dissolution were kept in a shaker incubator maintained at 37±0.5° for media for poorly water-soluble drugs include increasing 24 h. After shaking, the flasks were kept in an incubator the volume of the aqueous sink or removing the at 37±0.5° for equilibration for 12 h. Then the solution dissolved drug, solubilization of the drug by co-solvents was filtered through 0.45 µ membrane filter, and the (up to 40%), or by anionic or non-ionic surfactants (in post-micellar concentrations) or alteration of pH to enhance the solubility of insoluble drug molecules 4, 5 . The last two approaches seem less cumbersome and have been more widely employed in pharmacopoeial dissolution tests 6 .
In the present investigation, aqueous solubility of VAL in media containing co-solvents or surfactants was assessed to prepare a dissolution system which satisfies sink conditions for testing VAL formulations. The discriminating *For correspondence E-mail: n.udupa@manipal.edu filtrate was assayed spectrophotometrically at 239 nm against two respective blank solutions.
Dissolution experiments were performed using USP standard dissolution apparatus II (M/s Electrolab, Mumbai) at 37±0.5° at a paddle speed of 75 rpm. The dissolution medium was 900 ml of either water or a mixture of water and sodium lauryl sulphate (SLS) solution, selected on the basis of solubility data obtained from the experiments using 0.2, 0.5, 1, 1.5 or 2% w/v SLS in water. These mediums were also used to test the dissolution of bulk powder samples (100 mg, particle size < 200 µm) of VAL. Samples www.ijpsonline.com millipore filter. Same volume of fresh dissolution medium, maintained at 37±0.5°, was added to maintain constant volume. The dissolution medium was analyzed for VAL using UV method as described above. Results presented as dissolution medium. . m e d k n o w
In this study, solubility data was used as a basis for the development of a dissolution medium for VAL. Since VAL is poorly soluble in water, solubility determination was carried out using 0.6, 0.8, 1.0, 1.5 and 2.0% w/v of SLS in water; phosphate buffer pH 7.4, 0.5 and 1.0% v/v Tween in water; 5 and 10% methanol in water. The apparent solubility of VAL in different mediums is given in the
The comparative study of the dissolution rate of pure drug in water and in different ratios of SLS (0.25, 0.5, 1, 1.5, 2% w/v) containing water was carried out to justify the inclusion of SLS in fig.1 . The results indicated that dissolution rate of VAL increased with increase in SLS concentration of dissolution medium, and maximum dissolution was found in water containing 2% w/v SLS. Addition of surfactant to the dissolution medium improves the dissolution of pure drug by facilitating the drug release process at the solid / liquid interface and micelle solubilization in the bulk 7 . However, 0.6% w/v SLS will be sufficient as dissolution medium which has discriminating power when compared to lower concentrations. The solubility of a drug can be enhanced fig. 2 . The release rate of VAL from commercial formulations was determined. It was found that more than 85% of VAL was released from the formulations within 45 min under test conditions. The results of the present study clearly indicate that 0.6% w/v SLS in water, as dissolution medium, was suitable for routine in vitro dissolution testing of conventional VAL formulations.
